Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

SAN FRANCISCO, Jan. 3, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2018 at 11:00 a.m. Pacific Time.

The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://ir.nektar.com/events.cfm. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 11:30 a.m. Pacific Time. This Webcast will be available for replay until February 20, 2018.

About Nektar

Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585

SOURCE Nektar Therapeutics